Science

Science, technology and the emergence of AI have converged to make precision medicine for acute care a reality. This is how we deliver healthcare tailored to biology.

Research & Development

Evidence

Clinical Trials

The Sepsis ImmunoScore® Predicts Sepsis, Mortality, and Deterioration Better than Clinical Scores and Widely Available Biomarkers

Read More →

Products

Prenosis is developing a pipeline of integrated diagnostics and therapeutics grounded in each patient's unique biological profile, using deep data science and AI to give clinicians tools that reflect the true complexity of critical disease.

Immunix®

Sepsis ImmunoScore®

BioAegis Therapeutics Announces Collaboration with Prenosis to Advance AI-Driven Precision Medicine in Inflammatory Disease

Read More →

Resources

Blogs, articles, videos, and podcasts exploring how precision medicine and AI are changing the way clinicians detect and treat critical conditions.

Resource Library

Events

Treating the Patient, Not the Disease

Read More →

Newsroom

Read the latest Prenosis peer-reviewed articles and items from scholarly journals.

Newsroom

Sepsis ImmunoScore Outperforms Conventional Sepsis Tools

Read More →

About

As a biology-based technology company, we combine data science with AI to transform how critical conditions are diagnosed and treated.

Mission, Vision & Values

Careers

Leadership

Awards

LifeBridge Health deploys Prenosis’ FDA-authorized AI tool to speed sepsis detection

Read More →

Transforming Sepsis Care with AI: Prenosis Delivers Innovation

Labcorp Knowledge Library  |  Series  |  Brief Interviews with Healthcare Innovators

Interview originally published on Labcorp Knowledge Library September 19, 2025

Prenosis CEO and co-founder, Bobby Reddy, Jr. outlines the company’s mission to improve patient lives by tailoring healthcare to each person’s biology in this post as part of Labcorp’s Brief Interviews with Healthcare Innovators series, highlighting innovative companies in the Labcorp Venture Fund portfolio.

Jim Almas, MD, vice president and national medical director for clinical effectiveness, spoke with Bobby Reddy Jr., PhD, co-founder and CEO of Prenosis, a trailblazing startup that uses AI to redefine the standard of care for critical conditions.

Read the full interview >